[1] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. The Lancet, 2013, 381(9865): 468-475.
[3] Liaw Y F, Sung J J, Chow W C, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531.
[4] Zoutendijk R, Reijnders J G, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut, 2013, 62(5): 760-765.
[5] Chon H Y, Ahn S H, Kim Y J, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients[J]. Hepatol Int, 2021, 15(6): 1328-1336.
[6] Chen S, Zhou J, Wu X, et al. Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments[J]. Hepatol Int, 2024, 18 (3): 904-916.
[7] Sun Y, Chen W, Chen S, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events[J]. Clin Gastroenterol Hepatol, 2024, 22(3): 591-601.
[8] Sun Y, Zhou J, Wang L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450.
[9] Terrault N, Lok A, McMahon B, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
[10] 鲁凤民, 封波, 郑素军, 等.核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
[11] Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591.
[12] Lu Z, Sun Y, Chen S, et al. Multiple low-level viremia suggest hindered liver fibrosis regression in chronic hepatitis B patients during antiviral therapy[J]. J Viral Hepat, 2024, 31(12): 898-902.
[13] Kim J, Sinn D, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343.
[14] Allweiss L, Dandri M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156.
[15] Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J]. Gastroenterology, 2004, 126(7): 1750-1758.
[16] Dandri M, Burda M R, Will H, et al. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA[J]. Hepatology, 2000, 32(1): 139-146.
[17] Bowden S, Locarnini S, Chang T T, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine[J]. World J Gastroenterol, 2015, 21(15): 4644-4651.
[18] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54(9): 1100-1109.
[19] Hui R W H, Seto W K, Cheung K S, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study[J]. J Viral Hepat, 2018, 25(1): 97-104.
[20] Shi J, Fan J, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol, 2008, 23(9): 1419-1425.
[21] Mak L Y, Hui R W H, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806.
[22] Zhang M, Chen S, Wu X, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection[J]. J Med Virol, 2023, 95(10): e29156.
[23] Mak L Y, Hui R W H, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection[J]. Hepatol Int, 2021, 15(4): 901-911.
[24] Li J, Yang H I, Yeh M L, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224(2): 294-302.
[25] Van Kleef L A, Choi H S J, Brouwer W P, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3(5): 100350.
[26] Mao X, Cheung K S, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis[J]. Hepatology, 2023, 77(5): 1735.
[27] Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(4): 231-242.
[28] Seitz H K, Bataller R, Cortez-Pino H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 17.
[29] O′Shea R S, Dasarathy S, McCullough A J, et al. Alcoholic liver disease[J]. Hepatology, 2010, 51(1): 307-328.
[30] Martino C, Zaramela L S, Gao B, et al. Acetate reprograms gut microbiota during alcohol consumption[J]. Nat Commun, 2022, 13(1): 4630.
[31] Chung W G, Kim H J, Choe Y G, et al. Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection[J]. Clin Mol Hepatol, 2012, 18(2): 195.
[32] Hur M H, Yip T C F, Kim S U, et al. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B[J]. J Hepatol, 2025, 82(2): 235-244
[33] Zaborska V O, Ko H H, MacIsaac J, et al. Clinical characteristics and prevalence of hepatitis delta virus (HDV) infected individuals in British Columbia and Ontario: a multi-centre update[C]. 2024 AASLD Annual Meeting, Nov 15-19, 2024. San Diego, California, American Association for the Study of Liver Diseases. S134-S135.
[34] Xu H, Lin S, Yang L, et al. Recent seroprevalence and epidemiological characteristics of HDV infection among HBsAg-positive inpatients in China[C]. 2024 AASLD Annual Meeting, Nov 15-19, 2024. San Diego, California, American Association for the Study of Liver Diseases. S116-S117.
[35] Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062.
[36] Alfaiate D. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies[J]. J Hepatol, 2020, 73(3): 533-539.
[37] Wranke A, Serrano B C, Heidrich B, et al. Antiviral treatment and liver-related complications in hepatitis delta[J]. Hepatology, 2017, 65(2): 414-425.
[38] Wanless I R, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124(11): 1599-1607.
[39] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why?[J]. Liver Int, 2015, 35(Suppl 1): 78-81.
[40] Chen S, Wang B, Zhou J, et al. A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy[J]. J Med Virol, 2023, 95(2): e28555. |
